Altimmune, Inc. (ALT) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Altimmune, Inc.
Address
910 Clopper Road
Gaithersburg, MD 20878
United States of America (the)
Phone
240 654 1450
Website
Sector
Healthcare
Industry
Biotechnology
Employees
57
First IPO Date
May 26, 2017
Key Executives
| Name | Title | Pay | Year Born |
| Jerome Benedict Durso | Chairman, CEO & President | 50,941 | 1968 |
| Christophe Arbet-Engels | Chief Medical Officer | 361,356 | 1963 |
| Raymond Jordt | Chief Business Officer | 578,850 | 1973 |
| Gregory L. Weaver | Chief Financial Officer | 619,694 | 1956 |
| Scot Roberts | Chief Scientific Officer | 683,229 | 1959 |
| Tony Blandin | Vice President of Quality & Compliance Management | 0 | N/A |
| Andrew Shutterly | Principal Financial & Accounting Officer and Corporate Controller | 0 | 1988 |
| Bertrand Georges | Chief Technology Officer | 0 | N/A |
| Robin E. Abrams | Chief Legal Officer & Corporate Secretary | 0 | 1964 |
| Linda Richardson | Chief Commercial Officer | 0 | 1964 |
Description
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
